Clinical trial · Interventional
Impact of Exercise on Mitochondria in Cancer Patients.
The Impact of Short-term Exercise Programs on Mitochondrial Activity in Colorectal and Prostate Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim is to investigate the impact of prostate and colorectal cancer on mitochondrial quantity and quality along with muscle mass and function and whether this can be modified through the use of a home-based short-term exercise training program. The investigators aim to recruit participants awaiting curative surgery for colorectal and prostate cancer and to assess the variation in baseline mitochondrial activity between them. Participants from both cancer types will then carry out a 4 week home exercise program, this will be randomly allocated to either resistance-based or high-intensity interval training based. Participants will then be re-assessed on the day of their planned surgical procedure to assess the changes effected by the training program. The investigators hypothesize that there will be variation in mitochondrial activity linked to muscle mass across the two cancer types and that home-based exercise programs have the ability to improve mitochondrial activity along with muscle mass.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-intensity interval training | Other | — | UNRESOLVED |
| Resistance exercise training | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Resistance exercise training group
- description
- Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
- interventionNames
- Other: Resistance exercise training
- type
- EXPERIMENTAL
- label
- High-intensity interval training group
- description
- Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
- interventionNames
- Other: High-intensity interval training
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion criteria 1. Aged 50 years and over (no upper age limit) 2. Male patients 3. Histologically confirmed malignancy, radiologically or direct visualisation leading to high clinical suspicion of cancer with planned surgical resection as treatment option (prostate or colorectal). 4. Sufficient mobility to be able to complete a home-based exercise program 5. Capacity to give informed and written consent 6. Ability to travel to the RDH to complete the assessment session Exclusion criteria 1. Current participation in a formal exercise regime 2. Inability to complete exercise training 3. Inadequate level of the English language to be able to provide consent 4. A BMI \<16.5 or \>35 kg/m2 5. Active cardiovascular disease: 1. Uncontrolled hypertension (BP \> 160/100) 2. Angina 3. Heart failure (class III/IV) 4. Significant arrhythmia 5. Right to left cardiac shunt 6. Recent cardiac event 6. Taking beta-adrenergic blocking agents 7. Cerebrovascular disease: g. Previous stroke h. Aneurysm (large vessel or intracranial) i. Epilepsy 8. Respiratory disease including: j. Pulmonary hypertension k. Significant COPD l. Uncontrolled asthma 9. Clotting dysfunction or current use of anticoagulants (eg Warfarin/Clopidogrel/ Rivaroxaban) 10. Significant musculoskeletal or neurological disorders 11. Female patients 12. Those requiring or receiving neoadjuvant chemotherapy
References
Publications (0)
Data not yet available